The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems

被引:9
|
作者
Schreiner, Thomas Gabriel [1 ,2 ,3 ]
Menendez-Gonzalez, Manuel [4 ,5 ,6 ]
Popescu, Bogdan Ovidiu [1 ,7 ,8 ]
机构
[1] Univ Med & Pharm Carol Davila, Fac Med, Bucharest 050474, Romania
[2] Univ Med & Pharm Gr T Popa, Dept Neurol, Iasi 700115, Romania
[3] Gheorghe Asachi Tech Univ Iasi, Fac Elect Engn & Informat Technol, Dept Elect Measurements & Mat, Iasi 700050, Romania
[4] Univ Oviedo, Dept Med, Oviedo 33006, Spain
[5] Hosp Univ Cent Asturias, Dept Neurol, Oviedo 33006, Spain
[6] Inst Invest Sanitaria Principado Asturias, Oviedo 33006, Spain
[7] Colentina Clin Hosp, Neurol Dept, Bucharest 020125, Romania
[8] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest 050096, Romania
关键词
Alzheimer's disease; amyloid-beta; cerebrospinal fluid; therapy; implantable device; clearance; AMYLOID-BETA; MOUSE MODEL; NEPRILYSIN; CLEARANCE;
D O I
10.3390/biomedicines10071509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a global health problem, with incidence and prevalence considered to increase during the next decades. However, no currently available effective treatment exists despite numerous clinical trials in progress. Moreover, although many hypotheses are accepted regarding the pathophysiological mechanisms of AD onset and evolution, there are still many unknowns about the disorder. A relatively new approach, based on the amyloid-beta dynamics among different biological compartments, is currently intensely discussed, as it seems to offer a promising solution with significant therapeutic impact. Known as the "cerebrospinal-fluid-sink therapeutic strategy", part of the "three-sink therapeutic strategy", this theoretical model focuses on the dynamics of amyloid-beta among the three main liquid compartments of the human body, namely blood, cerebrospinal fluid, and the (brain) interstitial fluid. In this context, this article aims to describe in detail the abovementioned hypothesis, by reviewing in the first part the most relevant anatomical and physiological aspects of amyloid-beta dynamics. Subsequently, explored therapeutic strategies based on the clearance of amyloid-beta from the cerebrospinal fluid level are presented, additionally highlighting their limitations. Finally, the originality and novelty of this work rely on the research experience of the authors, who focus on implantable devices and their utility in AD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside
    Pawlowski, Matthias
    Meuth, Sven G.
    Duning, Thomas
    DIAGNOSTICS, 2017, 7 (03)
  • [2] Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimer's disease
    Wostyn, Peter
    Van Dam, Debby
    De Deyn, Peter Paul
    MEDICAL HYPOTHESES, 2019, 122 : 57 - 57
  • [3] Cerebrospinal fluid from Alzheimer’s disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer’s disease
    Jeongmin Lee
    Soo Jin Kwon
    Jang Hoon Kim
    Hyemin Jang
    Na Kyung Lee
    Jung Won Hwang
    Jong Hwa Kim
    Jong Wook Chang
    Duk L. Na
    Scientific Reports, 9
  • [4] Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease
    Lee, Jeongmin
    Kwon, Soo Jin
    Kim, Jang Hoon
    Jang, Hyemin
    Lee, Na Kyung
    Hwang, Jung Won
    Kim, Jong Hwa
    Chang, Jong Wook
    Na, Duk L.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] Cerebrospinal fluid biomarkers of Alzheimer’s disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 : 233 - 242
  • [6] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Holtzman, David M.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 51 - 63
  • [7] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Sui, Xiaojing
    Liu, Jianjun
    Yang, Xifei
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 233 - 242
  • [8] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Lee, K. H.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 41 - 42
  • [9] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Blennow, Kaj
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (02) : 413 - 417
  • [10] Cerebrospinal fluid shunting for Alzheimer's disease?
    Bennett, DA
    McDermott, MP
    NEUROLOGY, 2002, 59 (08) : 1126 - 1127